dry eye disease...introduction dry eye disease (ded) afflicts hundreds of millions of people...

IntroductionDry eye disease (DED) afflicts hundreds ofmillions of people throughout the world, is one ofthe most frequent causes of patient visits to eyecare practitioners, and has no cure. Moderate tosevere DED is associated with significant pain,limitations in performing daily activities, reducedvitality, poor general health, and oftendepression.

To increase our understanding of DED, the TearFilm & Ocular Surface Society (TFOS), a non-profit organization, launched the TFOS Dry EyeWorkshop II (TFOS DEWS II). This Workshopinvolved the efforts of 150 clinical and basicscience research experts from around the worldand required more than 2 years to complete.

The TFOS DEWS II report was published in theJuly 2017 issue, and the Executive Summary inthe October 2017 issue, of The Ocular Surfaceand downloadable versions are available on theTFOS website: www.TearFilm.org.

Some highlights of the conclusions andrecommendations of the TFOS DEWS II arepresented in this summary.

Figure 1. Classification of DED

Figure 2. Pathophysiology of DED

www.tearfilm.org

Dry Eye Disease What is it, why does it occur and how can it be diagnosed and treated?J. Daniel Nelson, Jennifer P. Craig, Lyndon Jones, Fiona J. Stapleton, Mark D.P. Willcox, James S. Wolffsohn and David A. Sullivan, on behalf of the participants in the TFOS Dry Eye Workshop II (TFOS DEWS IITM)

What is DED?TFOS DEWS II defined DED as follows:“Dry eye is a multifactorial disease of the ocularsurface characterized by a loss of homeostasis ofthe tear film, and accompanied by ocularsymptoms, in which tear film instability andhyperosmolarity, ocular surface inflammation anddamage, and neurosensory abnormalities playetiological roles.”DED is classified etiologically into two predominantand non-mutually exclusive categories: aqueousdeficient (ADDE) and evaporative (EDE) (Figure1). Most DED is evaporative in nature.The unifying characteristic of DED is the loss oftear film homeostasis. Such imbalance may bedetected as an abnormality in any one or more ofa myriad of tear film and ocular surface features.Why does DED occur?The core mechanism of DED is evaporation-induced tear hyperosmolarity, which is the hallmarkof the disease (Figure 2). It damages the ocularsurface both directly and by initiating inflammation,which can lead to a self-perpetuating, vicious cycleof DED. The major cause of EDE is meibomiangland dysfunction (MGD).

• Topical corticosteroid for longer duration• Amniotic membrane grafts• Surgical punctal occlusion

• Other surgical approaches (eg tarsorrhaphy, salivary glandtransplantation)

If above options are inadequate consider:

Consistent risk factors for DED include age, sex,race, MGD, connective tissue disease, Sjögrensyndrome, androgen deficiency, computer use,contact lens wear, estrogen replacement therapy,hematopoietic stem cell transplantation, certainenvironmental conditions (such as pollution, lowhumidity, and sick building syndrome) andmedication use (for example, antihistamines,antidepressants, anxiolytics, and isotretinoin).Iatrogenic DED is also common and can beinduced by a number of clinical interventions,including many topical and systemic drugs, andophthalmic surgical (e.g. refractive, cataract,glaucoma, vitreoretinal) and non-surgical (e.g.botulinum toxin application, cosmetic) procedures.How is DED diagnosed?TFOS DEWS II recommends a sequence of testsfor diagnosis of DED and assessment of itsseverity (Figure 3). This diagnostic process firstutilizes triaging questions to exclude conditions thatmimic DED. A DED diagnosis then requires apositive score on one of two specific symptomquestionnaires, followed by at least one positiveclinical sign indicating reduced non-invasive break-up time, elevated or a large interocular disparity inosmolarity, or ocular surface staining. How is DED treated?TFOS DEWS II also recommends a series ofstaged management and treatment options withproven efficacy, that aim to restore tear filmhomeostasis.These are listed in the Table below.

Acknowledgments: We thank Amy Gallant Sullivan and Sabrina Zappia (www.citynetonline.it) for their professional assistance with this TFOS DEWS IIhighlight report. A listing of Workshop participants, as well as a direct link to the entire TFOS report, can be found at: www.TearFilm.org.

www.tearfilm.org

Figure 3. Diagnostic approach for DED

STEP

1

STEP

2

STEP

3

STEP

4

• Oral secretagogues• Autologous/allogeneic serum eye drops

• Therapeutic contact lens options o Soft bandage lenses o Rigid scleral lenses

• Non-preserved ocular lubricants to minimize preservative-induced toxicity

• Tea tree oil treatment for Demodex (if present)• Tear conservation o Punctal occlusion o Moisture chamber spectacles/goggles• Overnight treatments (such as ointment or moisture chamberdevices)

• In-office, physical heating and expression of the meibomianglands (including device-assisted therapies)

• In-office intense pulsed light therapy for MGD• Prescription drugs to manage DED o Topical antibiotic or antibiotic/steroid combination applied to

the lid margins for anterior blepharitis o Topical corticosteroid (limited-duration) o Topical secretagogues o Topical non-glucocorticoid immunomodulatory drugs o Topical lymphocyte function-associated antigen-1 antagonist

drugs o Oral macrolide or tetracycline antibiotics



TFOS DEWS II recommendations for the staged management and treatment of DEDSTEP

1

2

3

4

• Education regarding the condition, its management, treatmentand prognosis

• Modification of local environment• Education regarding potential dietary modifications (includingoral essential fatty acid supplementation)

• Identification and potential modification/elimination of offendingsystemic and topical medications

• Ocular lubricants of various types (if MGD is present, thenconsider lipid-containing supplements)

• Lid hygiene and warm compresses of various types

lable at ScienceDirect

The Ocular Surface xxx (2017) 1e11

Contents lists avai

The Ocular Surface

journal homepage: www.theocularsurface.com

TFOS DEWS II Report Executive Summary

Jennifer P. Craig a, 1, J. Daniel Nelson b, c, 1, Dimitri T. Azar d, Carlos Belmonte e, f,Anthony J. Bron g, h, Sunil K. Chauhan i, Cintia S. de Paiva j, Jos�e A.P. Gomes k,Katherine M. Hammitt l, Lyndon Jones m, Jason J. Nichols n, Kelly K. Nichols n,Gary D. Novack o, p, Fiona J. Stapleton q, Mark D.P. Willcox q, James S. Wolffsohn r,David A. Sullivan i, *

a Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealandb Department of Ophthalmology, HealthPartners Medical Group and Clinics, St Paul, MN, USAc Department of Ophthalmology, University of Minnesota, Minneapolis, USAd University of Illinois at Chicago College of Medicine, Chicago, IL, USAe Instituto de Neurociencias de Alicante, University Miguel Hernandez-CSIC, Spainf Instituto Fernandez-Vega, Oviedo University, Spaing Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKh Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, UKi Schepens Eye Research Institute, Massachusetts Eye and Ear, and Department of Ophthalmology, Harvard Medical School, Boston, MA, USAj Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USAk Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo/Paulista School of Medicine, Sao Paulo, Brazill Sj€ogren's Syndrome Foundation, Bethesda, MD, USAm Centre for Contact Lens Research, School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canadan University of Alabama at Birmingham School of Optometry, Birmingham, AL, USAo Pharma Logic Development, San Rafael, CA, USAp Departments of Pharmacology and Ophthalmology, University of California, Davis, School of Medicine, USAq School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australiar School of Life and Health Sciences, Aston University, Birmingham, UK

a r t i c l e i n f o

Article history:Received 2 August 2017Accepted 4 August 2017

* Corresponding author. Schepens Eye Research IBoston, MA 02114, USA.

E-mail address: [email protected] Co-first author.

http://dx.doi.org/10.1016/j.jtos.2017.08.0031542-0124/© 2017 Elsevier Inc. All rights reserved.

Please cite this article in press as: Craig JP, etj.jtos.2017.08.003

a b s t r a c t

This article presents an Executive Summary of the conclusions and recommendations of the 10-chapterTFOS DEWS II report. The entire TFOS DEWS II report was published in the July 2017 issue of The OcularSurface. A downloadable version of the document and additional material, including videos of diagnosticand management techniques, are available on the TFOS website: www.TearFilm.org.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

Dry eye disease (DED) affects hundreds of millions of peoplethroughout the world and is one of the most frequent causes ofpatient visits to eye care practitioners. It is a symptomatic disease,characterized by a vicious cycle of tear film instability and hyper-osmolarity, which leads to increased ocular surface inflammation,damage and neurosensory abnormalities. Moderate to severe DEDis associated with significant pain, limitations in performing daily

nstitute, 20 Staniford Street,

du (D.A. Sullivan).

al., TFOS DEWS II Report Exec

activities, reduced vitality, poor general health, and oftendepression.

To increase our understanding of DED, the Tear Film & OcularSurface Society (TFOS), a non-profit organization, launched theTFOS Dry Eye Workshop II (TFOS DEWS II) in March 2015 [1]. Thisinitiative reflected the TFOS mission, which is to advance theresearch, literacy, and educational aspects of the scientific field ofthe tear film and ocular surface. The goal of the TFOS DEWS II was toachieve a global consensus concerning multiple aspects of DED.More specifically, TFOS DEWS II sought to: 1) Update the definitionand classification of DED; 2) Evaluate critically the epidemiology,pathophysiology, mechanism, and impact of this disorder; 3)Develop recommendations for the diagnosis, management andtherapy of this disease; and 4) Recommend the design of clinical

utive Summary, The Ocular Surface (2017), http://dx.doi.org/10.1016/

http://www.TearFilm.orgmailto:[email protected]/science/journal/15420124www.theocularsurface.comhttp://dx.doi.org/10.1016/j.jtos.2017.08.003http://dx.doi.org/10.1016/j.jtos.2017.08.003http://dx.doi.org/10.1016/j.jtos.2017.08.003

J.P. Craig et al. / The Ocular Surface xxx (2017) 1e112

trials to assess future interventions for DED treatment.The TFOS DEWS II involved the efforts of 150 clinical and basic

science research experts from around the world, who utilized anevidence-based approach and a process of open communication,dialogue and transparency to increase our understanding of DED.This process required more than 2 years to complete.

The entire TFOS DEWS II report was published in the July 2017issue of The Ocular Surface. A downloadable version of the docu-ment and additional material, including videos of diagnosticand management techniques, are available on the TFOS website:www.TearFilm.org. It is anticipated that translations of the reportwill be offered in many languages, including, but not limited to,Chinese, French, German, Italian, Japanese, Korean, Polish, Portu-guese, Romanian, Spanish, Turkish and Vietnamese. These trans-lations, when completed, will be available on the TFOS website.

An Executive Summary of the conclusions and recommenda-tions of the TFOS DEWS II report is presented in this article. Thematerial is abstracted from the reports of ten TFOS DEWS II Sub-committees, which were Definition and Classification; Epidemi-ology; Sex, Gender, and Hormones; Pathophysiology; Tear Film;Iatrogenic Dry Eye; Pain and Sensation; Diagnostic Methodology;Management and Therapy; and Clinical Trial Design. Additionaldetails and all references can be obtained in the open access, onlineversion.

2. Definition and classification [2]

The goals of the TFOS DEWS II Definition and ClassificationSubcommittee were to create an evidence-based definition and acontemporary classification system for DED. The new definition isas follows:

“Dry eye is a multifactorial disease of the ocular surface char-acterized by a loss of homeostasis of the tear film, and accom-panied by ocular symptoms, in which tear film instability andhyperosmolarity, ocular surface inflammation and damage, andneurosensory abnormalities play etiological roles.”

The terminology in this definition, including diction, word order,emphasis, and accepted meaning, was critical in creating an inter-nationally accepted definition. The term “multifactorial disease”recognizes DED as a significant and complex, functional disorderthat cannot be characterized by a single process, sign or symptom.The term “ocular surface” is defined as comprising the structures ofthe ocular surface and adnexa, including the tear film, lacrimal andmeibomian glands, cornea, conjunctiva and eyelids. “Homeostasis”describes a state of dynamic equilibrium in the bodywith respect toits various functions, and to the chemical composition of the fluidsand tissues. Disruption of homeostasis is considered to be theunifying characteristic that encompasses the myriad of signs of tearfilm and ocular surface imbalance that might be observed in DED.The term “symptoms” embraces a broad range of possible patient-reported experiences associated with DED including, but notlimited to, discomfort and visual disturbance. The key elementscontributing to the pathophysiological process, including tear filminstability, hyperosmolarity, inflammation and damage, recognizedas etiological triggers of the vicious circle, were deemed important,along with neurosensory abnormalities, which have featuredincreasingly in the recent literature, for inclusion in the definition.

In the classification of DED, the latest evidence supports ascheme based on its pathophysiology in which aqueous deficientdry eye (ADDE) and evaporative dry eye (EDE) exist as a continuum,such that elements of each need to be considered in diagnosis andmanagement. This approach is not intended to override clinicalassessment and judgment but to help guide clinical management

Please cite this article in press as: Craig JP, et al., TFOS DEWS II Report Execj.jtos.2017.08.003

and future research.The Subcommittee's recommended classification of DED is

shown in Fig. 1. The upper portion of the figure represents a clinicaldecision algorithm, beginning with the assessment of symptoms,and followed by review for signs of ocular surface disease. DEDexhibits both symptoms and signs, and can be differentiated fromother ocular surface disease with the use of triaging questions andancillary testing. It is to this DED group that diagnostic subtyping,and conventional DEDmanagement strategies, apply. Symptomaticpatients without demonstrable clinical signs do not fall into theDED group, but are differentiated into pre-clinical ocular surfacedisease or neuropathic pain (non-ocular surface disease).Conversely, asymptomatic patients exhibiting signs are differenti-ated into patients with poor corneal sensitivity, or those withprodromal signs, who may be at risk of developing manifest DEDwith time or provocation, for example following ophthalmic sur-gery or contact lens fitting. Finally, the option exists for patientswithout either signs or symptoms to be classified, according to theflow chart, as ‘normal’.

The lower portion of Fig. 1 represents the etiological classifica-tion of DED, and highlights the two predominant and non-mutuallyexclusive categories; ADDE and EDE. Epidemiological and clinicalevidence suggest that the preponderance of DED is evaporative innature, which is reflected by devotion of a greater proportion ofFig. 1 to EDE than to ADDE. While it is possible that ADDE can occurwithout obvious signs of EDE and vice versa, as DED progresses, it isincreasingly likely that characteristics of both ADDE and EDE willbecome evident. Further subclassification of ADDE and EDE is notdetailed in Fig. 1, but is acknowledged to relate to a vast range ofconditions, as described in the TFOS DEWS II Pathophysiologyreport. ADDE describes conditions affecting lacrimal gland func-tion. EDE is recognized to include both lid-related (for example,meibomian gland dysfunction [MGD] and blink-related) and ocularsurface-related (such as mucin and contact lens-related) causes.

3. Epidemiology [3]

The TFOS DEWS II Epidemiology report examines literature onthe prevalence, incidence, risk factors, natural history, andmorbidity and reviewed questionnaires used in epidemiologicalstudies of DED. The report focuses on epidemiological studiespublished since the previous TFOS DEWS report in 2007. A meta-analysis of all published prevalence data was undertaken to esti-mate the impact of age (Table 1) and sex on symptoms and signs ofDED. Global mapping of DED prevalence was undertaken usinggeospatial analysis. The report summarizes the available evidenceon the epidemiology of DED and provides recommendations forfuture needs and opportunities.

DED epidemiology continues to be challenged by the failure fora standardized definition and diagnostic criteria to be used.Consequently, the report describes prevalence based on commonlyused diagnostic criteria, including those based on symptoms, onself-report of a practitioner diagnosis, and on DED signs.

While much new information has been published in the last10 years, no population studies have reported on prevalence ofDED for populations south of the equator. Much of the attentionhas focused on Asia and Europe. The prevalence of DED, with andwithout symptoms, ranged in prevalence from 5 to 50%. DEDprevalence based on signs alone was generally higher and morevariable, reaching up to 75% in some populations. Criteria forpositive DED signs varied between studies and it was acknowl-edged that some signs may reflect secondary outcomes or may berelated to normal aging. Very few studies were conducted inyounger populations (less than 40 years of age) but indicationsare that DED is also prevalent in these populations. The evidence


http://www.tearfilm.org

Fig. 1. DED classification scheme. Please see the original report for a complete description of this figure [2].

J.P. Craig et al. / The Ocular Surface xxx (2017) 1e11 3

for Asian race as a risk factor for DED now appears mostlyconsistent.

The meta-analysis confirmed that symptomatic disease andsigns of DED increase with age, however prevalence of signsshowed a greater increase per decade than symptomatic disease.Higher rates of DED are reported in women than men, althoughthe differences generally become significant only with increasingage.

Risk factors were categorised as consistent, probable, andinconclusive, in line with the previous TFOS DEWS report [4]. Age,sex, race, MGD, connective tissue disease, Sj€ogren syndrome,androgen deficiency, computer use, contact lens wear, estrogenreplacement therapy, hematopoietic stem cell transplantation,certain environmental conditions (such as pollution, low humid-ity, and sick building syndrome) and medication use (for example,antihistamines, antidepressants, anxiolytics, and isotretinoin)were identified as consistent risk factors. Probable risk factorsincluded diabetes, rosacea, viral infection, thyroid disease, psy-chiatric conditions, pterygium, low fatty acid intake, refractivesurgery, allergic conjunctivitis, and additional medications (e.g.anti-cholinergic, diuretics, b-blockers). Inconclusive DED risks areHispanic ethnicity, menopause, acne, sarcoidosis, smoking,alcohol, pregnancy, demodex infestation, botulinum toxin injec-tion, multivitamins and oral contraceptives.


The economic burden on society and impact of DED on the in-dividual, through its detrimental effect on vision, quality of life, andwork productivity, as well as the psychological and physical impactof pain, are considerable. The most significant costs are indirectcosts due to reduced work productivity. Questionnaires used toevaluate DED vary in their utility for epidemiological studies andfurther evidence for normative ranges and clinically significantchanges are required.

Future research needs include better evaluation of the preva-lence of DED of varying severity and in youth, the incidence ofdisease in different populations, and the impact of modifiable riskfactors such as mobile device usage. Geographical mapping ap-proaches will further allow the impact of climate, environment andsocioeconomic factors on DED to be elucidated. There has beenlimited study of the natural history of both treated and untreatedDED and this remains an important area for future research.

4. Sex, gender, and hormones [5]

One of the most compelling features of DED is that it occursmore frequently in women than in men. In fact, the female sex is asignificant risk factor for the development of DED. That such a sex-related variation exists in the prevalence of an eye disease, or anyother ocular function, should not be a surprise, as sex-related


Table 1Regression analysis of prevalence data by age for each diagnostic subgroup.

Diagnostic subgroup N of studies Slope estimate (per decade of age) Std error of slope estimate p-value (H0: slope ¼ 0) R2

1. Symptoms or OSDI � 23 8 3.43 0.57 0.001 0.8582. Self-report of a clinician diagnosis of dry eye 8 2.01 0.73 0.034 0.5563. WHS Criteria 8 �0.44 0.57 0.475a 0.088b4. Schirmer 5 10.55 1.78 0.010 0.921b5. Tear break up time 5 9.71 1.20 0.004 0.956b6. Corneal staining 5 7.63 1.67 0.020 0.875b7. MGD 5 5.23 1.44 0.036 0.815

OSDI -Ocular SurfaceDisease Index;WHS-Women'sHealth Study;MGD-meibomianglanddysfunction. Please see theoriginal report for a complete descriptionof thisfigure [3].a Indicates that there is no change in prevalence by age for the WHS criteria.b Regression analyses are based on estimates of prevalence from age 40e49 and beyond (i.e., missing values for prevalence for ages 15e18, 19e29, and 30e39).


differences are present in almost every cell, tissue and organ systemof the body. Indeed, since 1945, more than 575,000 scientific re-ports have been published which address the basic and/or clinicalimpact of sex on human physiology and pathophysiology.

The TFOS DEWS II Sex, Gender, and Hormones report detailsnumerous sex-related differences that have been identified in theeye. Many of these differences have been attributed to the effects ofsex steroids (e.g. androgens and estrogens), hypothalamic-pituitaryhormones, glucocorticoids, insulin, insulin-like growth factor 1 andthyroid hormones. For example, androgens are extremely impor-tant in the regulation of the ocular surface and adnexa. They appearto mediate many of the sex-related differences in these tissues.Androgen deficiency, in turn, predisposes to lacrimal glanddysfunction, serves as a risk factor for MGD, and is associated withthe development of both ADDE and EDE. In contrast to androgens,the role of estrogens at the ocular surface is less well defined, witheffects that appear to be sex-, tissue-, and dose-specific.

In addition, sex-related differences may arise from the sexchromosome complement, including differences in parent-of-origin effects, X chromosome gene dosage (e.g. X-inactivation)and genes in the non-recombining region of the Y chromosome, aswell as from sex-specific autosomal factors and epigenetics (e.g.microRNAs, DNA methylation and acetylation, histonemodifications).

It is important to note that the word “sex” is used for a reason.Although “sex” and “gender” are often used interchangeably, theyhave distinct meanings. As stated in a 2001 report by the Instituteof Medicine [6], “sex” refers to the classification of living things,generally as male or female, according to their reproductive organsand functions assigned by chromosomal complement. “Gender”refers to a person's self-representation as a man or woman, or howsocial institutions respond to that person based on the individual'sgender presentation. Gender is rooted in biology, but is shaped byenvironment and experience. In other words, sex distinguishesmales and females based on their biological characteristics. Gender,in turn, reflects socially constructed characteristics such as behav-iors and expectations related to being a man, masculine, or being awoman, feminine. Furthermore, gender is dynamic, context-relatedand operates on a spectrum.

In effect, both sex and gender affect health and disease, as wellas patients' perceptions about their health. Gender also affects in-dividuals' access to and interactions with the health care system.Many health disparities are associated with gender. Disparitiesarise from a range of influences that are biological, behavioral/perceptual, cultural, and societal. Therefore, both sex and gender-dterms that are distinguishable, but intertwined, should beconsidered, as they both have pronounced effects on health and onhealth disparities. Gender and biological sex affect DED risk, pre-sentation of the disease, immune responses, pain, care-seekingbehaviors, service utilization, and a myriad of other facets of eyehealth.


Overall, sex, gender and hormones play a major role in theregulation of ocular surface and adnexal tissues, and in the differ-ence in DED prevalence between women and men.

5. Pathophysiology [7]

On the basis of peer-reviewed literature, the TFOS DEWS IIPathophysiology Subcommittee concluded that the core mecha-nism of DED is evaporation-induced tear hyperosmolarity, which isthe hallmark of the disease. It damages the ocular surface bothdirectly and by initiating inflammation. The cycle of events,described as the Vicious Circle of DED, is shown at the center ofFig. 2.

Two forms of DED are recognized, ADDE and EDE. In ADDE, tearhyperosmolarity results when lacrimal secretion is reduced, inconditions of normal evaporation from the eye. In EDE, tearhyperosmolarity is caused by excessive evaporation from theexposed tear film in the presence of a normally functioning lacrimalgland. Since tear osmolarity is a function of tear evaporation ineither ADDE or EDE, tear hyperosmolarity arises due to evaporationfrom the ocular surface and, in that sense, all forms of DED areevaporative. In other words, EDE is more accurately considered ahyper-evaporative state.

In DED, tear hyperosmolarity is considered to be the trigger for acascade of signaling events within surface epithelial cells, whichleads to the release of inflammatory mediators and proteases. Suchmediators, together with the tear hyperosmolarity itself, are un-derstood to cause goblet cell and epithelial cell loss and damage tothe epithelial glycocalyx. Inflammatory mediators from activated T-cells, recruited to the ocular surface, reinforce damage. The netresult is the characteristic punctate epitheliopathy of DED and atear film instability which leads at some point to early tear filmbreakup. This breakup exacerbates and amplifies tear hyper-osmolarity and completes the vicious circle events that lead toocular surface damage. Ultimately this is thought to lead to self-perpetuation of the disease.

Tear film instability can be initiated without the prior occur-rence of tear hyperosmolarity, by conditions that affect the ocularsurface, including xerophthalmia, ocular allergy, topical preserva-tive use and contact lenswear. In this case, early tear film breakup ishypothesized to be the primary basis for tear film hyperosmolarityinitially experienced locally at the site of breakup, and withincreasing severity, at some point becoming detectable in tearmeniscus samples. This represents an ocular surfaceerelated formof EDE. In MGD-related EDE tear hyperosmolarity results from atear film lipid layer deficiency. In ADDE the onset of early breakupduring the evolution of the disease, may add a secondary evapo-rative element to the DED.

There are various causes of ADDE. It may result from blockingthe sensory drive to the lacrimal gland that is essential to maintaintear film homeostasis. Bilateral topical anesthesia can cause both a


Fig. 2. Pathophysiology of DED. Please see the original report for a complete description of this figure [7].


reduction in tear secretion and blink rate. DED due to a block inreflex tearing can be caused by chronic abuse of topical anesthetics,trigeminal nerve damage and refractive surgery including LASIKsurgery. The delivery of aqueous tears to the tear sac can also bereduced by obstruction to the lacrimal ducts, which might occur inany form of cicatricial conjunctival disease, such as trachoma,ocular cicatricial pemphigoid, erythema multiforme, graft-versus-host-disease and chemical burns. A number of drugs in systemicuse, such as antihistamines, b-blockers, antispasmodics, diureticsand some psychotropic drugs, can cause a reduction in lacrimalsecretion and are risk factors for DED [3,8]. Also, tear secretion ratefalls in later life.

In the Western world the most common cause of ADDE is in-flammatory infiltration of the lacrimal gland, encountered mostseverely in the DED associated with autoimmune disorders such asSj€ogren syndrome (SSDE) and, with lesser severity, in non-Sj€ogrensyndrome (NSDE). Inflammation causes both acinar and ductalepithelial cell dysfunction and/or destruction and a potentiallyreversible neurosecretory block. Circulating antibodies to themuscarinic (M3) receptor may also cause a receptor block. Lowtissue androgen levels may predispose to lacrimal glandinflammation.

Epithelial injury and defective glycocalyx, loss of tear volumeand of goblet cell mucin, lead to increased frictional damage andfriction-related symptoms. The tear hyperosmolarity and epithelialinjury caused by DED stimulates corneal nerve endings, leading tosymptoms of discomfort, increased blink rate and potentially, to acompensatory, reflex increase in lacrimal tear secretion. Thiscompensatory secretion is more likely in EDE, where lacrimal glandfunction is potentially normal.

A schematic diagram to show the etiology and mechanism ofMGD, which is the major cause of EDE, is shown in Fig. 3. Although


many mechanistic aspects are not yet understood, the figure at-tempts to summarize the current view. The upper part of the figureillustrates the etiology of the two forms of MGD that result in lowdelivery of meibum, cicatricial and non-cicatricial MGD.

With age, there is an increase in meibomian gland dropout,particularly after the age of 50 years, which correlates with theappearance of primary MGD. A fall in bioavailable androgens maycontribute to these events. In youth, treatment of acne vulgariswith cis-retinoic acid may induce gland atrophy and MGD, while inan older age group, androgen receptor insensitivity or blockademay induce signs of MGD. The anti-glaucoma drugs pilocarpine andtimolol also have direct effects on human meibomian glandepithelial cells that may influence their morphology, survival and/or proliferative capacity, and possibly promote MGD. Poly-chlorinated biphenyls may cause a systemic disorder that includesMGD-like features. Certain skin disorders, such as acne rosacea,atopic dermatitis, seborrheic dermatitis and psoriasis are associ-ated with non-cicatricial MGD, while cicatricial conjunctival dis-eases such as trachoma, erythema multiforme and pemphigoid,lead to cicatricial MGD.

A key event in non-cicatricial MGD is hyperkeratinization ofthe terminal ducts, leading to duct obstruction, duct dilatationand disuse atrophy of the glands. Later, obliteration of the glandorifices may occur. Obstruction may be exacerbated by changes inoil composition that increase meibum viscosity. The degree towhich inflammatory changes are found around affected glandsvaries in different reports, but signs of inflammation are commonat the lid margin. Inflammatory mediators and lipids may bereleased into tears and onto the ocular surface to cause epithelialdamage. In cicatricial MGD, submucosal conjunctival scarringdrags the meibomian orifices, terminal ducts and mucocutaneousjunction posteriorly, across the posterior lid border and onto the


Fig. 3. Pathophysiology of MGD. Please see the original report for a complete description of this figure [7].


tarsal plate, where the narrowed and displaced ducts can nolonger deliver meibum effectively to the tear film lipid layer. Lowmeibum delivery and changes in oil composition can lead to tearfilm instability, increased tear evaporation and ultimately to EDE.In low delivery MGD, symptoms may arise from the local lid dis-ease itself, from lid disease with ocular surface damage and fromEDE.

6. Tear film [8]

The TFOS DEWS II Tear Film Subcommittee recommended atwo-phasemodel of the tear film, which has a lipid layer overlying amuco-aqueous phase. Wax and cholesteryl esters (non-polar lipids)make up the majority of the tear lipid layer and these are spreadonto the muco-aqueous layer by an underlying layer of polar lipids,including (O-acyl)-u-hydroxy fatty acids and possibly phospho-lipids. The role of the tear film lipid layer alone in preventingevaporation and breakup of tears on the eye is controversial. It islikely that interactions of the whole tear film, including lipids,mucins, proteins and salts, prevent evaporation and collapse, butfurther work is needed to confirm this together with the relativeroles of the various components.

Several studies have attempted to correlate changes in tear lipidbiochemistry with DED, but no definitive linkage has yet beenmade. In contrast, tear osmolarity received considerable attentionas the hallmark of DED, increasing with the severity of DED.

The muco-aqueous layer overlies the apical epithelial cells andtheir carbohydrate-rich glycocalyx. Changes in the amount ofmucin or the glycosylation of different components have been re-ported in tears collected from DED patients. The muco-aqueouslayer contains at least four major mucins, and over 1500 different


proteins and peptides. Tear proteins have been reported to differ intears from DED subjects, but no definitive set of proteins or theirdegrees of change are yet validated to aid diagnosis. This is an areathat should receive increased attention.

Changes to the tear film clearly occur in DED. However, the lackof unified clinical parameters in tear film studies and the relativelylimited understanding of the structure of the tear film hashampered comprehension of how these changes occur and theirsignificance in the pathophysiology of DED. Improvements in theability to characterize the biochemistry of the tear film may lead tothe identification of new markers that can be used to diagnose,potentially predict, and even treat DED. A holistic approach tounderstanding tear film structure and function will undoubtedlylead to better treatments for patients with this disease.

7. Pain and sensation [9]

As noted by the TFOS DEWS II Pain & Sensation Subcommittee,pain can be differentiated into nociceptive and neuropathic types.Nociceptive pain occurs in response to actual or threatened damageto tissues. However, neuropathic pain occurs due to a lesion withinthe somatosensory nervous system and is commonly referred to aspathologic pain or pain without biological value.

Pain associatedwith DED is transmitted via the peripheral axonsof trigeminal ganglion (TG) neurons innervating the cornea andconjunctiva. Within the corneal stroma, they form a subepithelialnerve plexus whose ascending branches ramify extensively toterminate within the surface epithelial layers. Functionally, sensorynerves belong to polymodal nociceptor neurons, pure mechano-nociceptor neurons and cold thermoreceptor neurons. Polymodalnociceptors are normally silent and respond to chemical,


Fig. 4. Diagram summarizing how ocular inflammation of various etiologies or ocular surface drying in DED, provoke variable increases (þ) or decreases (�) of nerve impulseactivity in polymodal- and mechano-nociceptors and in cold thermoreceptors of the high background, low threshold (HB-LT) and low background, high threshold (LB-HT) types.Together these changes elicit conscious sensations of different quality, as well as changes in tear flow and in spontaneous and reflex blinking.


mechanical, and thermal stimuli. The inflammatory mediatorsreleased during injury sensitize them. The transient receptor po-tential cation channel subfamily V member 1 (TRPV1) is importantfor sensory transduction and sensitization of polymodal noci-ceptors. Pure mechano-nociceptors are also silent at rest andrespond only to mechanical forces perhaps through piezo2 andother non-identified transducing channels. Cold thermoreceptorscontinuously discharge nerve impulses at the normal eye surfacetemperature, respectively augmenting or decreasing the basalfiring frequency with cooling or warming. TRPM8 is their main coldtransducing channel and is also sensitive to osmolarity increases.Inter-blink tear evaporation causes discrete cooling of the ocularsurface and tear osmolarity rises, thereby augmenting basal activityof cold thermoreceptors. This is consistent with the hypothesis thatcold-sensitive fibers contribute to the reflex control of basal tearproduction and blinking.

The TG neurons from the ocular surface project primarily intotwo spatially discrete regions within the trigeminal brain stemnuclear complex: the transition region between caudal Vi and Vc(ViVc transition) and at the Vc/upper cervical cord junction (VcC1region). Evidence suggests that the VcC1 region plays a dominantrole in sensory-discriminative aspects of ocular pain. ViVc transi-tion neurons are excited by bright light and are activated bychanges in themoisture status of the ocular surface. Ocular neuronsat the ViVc transition project to brain regions that control lacri-mation (superior salivatory nucleus) and blinking (facial motornucleus) as well as to the sensory thalamus. Thus, it is suggestedthat ocular neurons at the ViVc transition play a significant role inmaintaining ocular surface homeostasis.

The secretory activity of the main lacrimal gland is regulatedby autonomic sympathetic and parasympathetic nerves whoseactivity is regulated by reflex influences from sensory neuronssupplying the ocular surface. Parasympathetic innervation is moreextensive. Very little is known about the neural control of acces-sory lacrimal glands, but it appears to be similar to the mainlacrimal gland. While nerves are present around the meibomianglands, there are no studies examining the role of sensory orautonomic nerves and their neurotransmitters in regulating theholocrine secretion of the meibomian gland. Activation of sensorynerves supplying the rat cornea evokes goblet cell mucoussecretion; however efferent nerve type(s) involved in this reflexresponse remain to be established. Several non-neural processesregulate the release of mucins from stratified squamous cells, but


to date no regulatory role for nerves or neurotransmitters hasbeen identified.

In addition to regulation of tear production, ocular surfacenerves mediating sensations contribute to blinking behavior(Fig. 4). It has been suggested that spontaneous blinking is main-tained, at least in part by the continuous nerve impulse firing of eyesurface cold thermoreceptors, an effect likely mediated by theconnections of TG neurons with brainstem Vi/Vc neurons which inturn project to the motor neurons of the facial nerve (Cranial nerveVII). Nociceptor sensory input, projecting to neurons at the VcC1region, initiates reflex blinking through their projections to ViVctransition neurons, and sets blink amplitude and peak velocity ofcorneal reflex blinks.

In DED, reduced tear secretion leaves the corneal epitheliumexposed to adverse environmental conditions and often leads tovariable levels of inflammation and to peripheral nerve terminaldamage. Inflammation causes sensitization of polymodal noci-ceptors and mechano-nociceptors, while it depresses cold ther-moreceptor activity. However, in experimental DED thesensitization of nociceptor fibers is discrete and the most promi-nent nerve disturbance is the sustained, abnormal increase in coldthermoreceptor nerve activity that occurs in parallel withmorphological changes in corneal innervation. This suggests thatdryness-induced nerve damage dominates over inflammation,causing abnormal activity primarily in cold terminals. In parallelwith these changes in peripheral nerve activity, brainstem ocularneurons at both ViVc and VcC1 regions display enhancedresponsiveness.

8. Iatrogenic dry eye [10]

As reported by the TFOS DEWS II Iatrogenic Dry Eye Subcom-mittee, DED can be caused by a variety of iatrogenic interventions,including topical and systemic drugs, the use of contact lenses, andophthalmic surgical and non-surgical procedures.

Topical medications that cause DED (Table 2) interact with theocular surface by exerting allergic, toxic and immuno-inflammatoryeffects. Preservatives, such as benzalkonium chloride, may cause oraggravate DED through their toxic and proinflammatory effects, aswell as detergent tensioactive properties. Moreover, a great varietyof systemic drugs, such as vasodilators, sulfonylureas, anxiolytics,antidepressants, antihistamines, and those listed in Table 3, mayalso induce DED secondary to decreased tear production, altered


Table 2Examples of topical treatments that may induce or worsen DED.

Compounds Examples

Adrenergic agonists Apraclonidine, Brimonidine, DipivefrinAnti-allergics Emedastine, OlopatadineAnti-virals Aciclovir, Idoxuridine, Trifluridineb�blockers Betaxolol, Carteolol, Levobunolol, Metipranolol, TimololCarbonic anhydrase inhibitors Brinzolamide, DorzolamideCholinergic agonists Pilocarpine, EcothiopateDecongestants Naphazoline, TetryzolineMiotics DapiprazoleMydriatics & cyclopegics Cyclopentolate, Tropicamide, HydroxyamfetamineProstaglandins Bimatoprost, Latanoprost, Travoprost, UnoprostoneTopical and local anesthetics Cocaine, Proxymetacaine, TetracaineTopical ocular non-steroidal anti-inflammatory drugs Bromfenac, Diclofenac, Ketorolac, Nepafenac

Table 3Known or suspected systemic medications causing, contributing to, or aggravatingDED.

Category Subcategory

Analgesic AntirheumaticCannabinoidOpioid

AnesthesiaAnticholinergic (antimuscarinic) Antiarrythmic/Bronchodilating

AntihistamineAntidepressantAnti-Parkinson'sAntipsychoticAntispasmodicDecongestant

Antihypertensive Adrenergic blockingNaþCl- Co-transporter (diuretic)

AntileprosyAntimalarialAntineoplasticAnxiolytic/hypnoticChelator/Calcium RegulatorDepressantHerbal and VitaminsHormonal Antiandrogen/Estrogen replacementNeurotoxinSedative


nerve input and reflex secretion, inflammatory effects on secretoryglands, or direct irritation effect through secretion into the tears.

DED in contact lens wearers has been identified as an ongoingissue for many patients. The use of contact lenses can either induceor be associated with DED. Biophysical changes to the tear film incontact lens wearers with DED include a thinner, patchy lipid layer;tear film instability; lower basal tear turnover rate; and decreasedtear meniscus volume.

Surgical procedures such as corneal refractive surgery and ker-atoplasty may cause or aggravate DED through mechanismsintrinsic to the procedure (i.e. corneal nerve transection) or even bythe use of postoperative topical drugs. Cataract surgery, lid sur-geries, botulinum toxin application and cosmetic procedures arealso considered risk factors for iatrogenic DED, which can be thecause of patient dissatisfaction, visual disturbance and poor surgi-cal outcomes.

Future directions to address iatrogenic DED include more indepth epidemiological studies about the risk factors, developmentof less toxic medications and preservatives, as well as new tech-niques for less invasive eye surgeries. Novel research into detectingearly DED prior to ocular surgery, determining the benefits of


prophylactic treatment, as well as efforts to establish appropriatetherapeutics, and improving attempts to regulate and overseemedications, preservatives and procedures should be considered.

9. Diagnostic methodology [11]

The TFOS DEWS II Diagnostic Methodology Subcommitteeexamined the research evidence for tests to quantify patientsymptoms, visual disturbance, tear film stability, osmolarity, tearvolume, ocular surface damage, inflammation of the ocular surfaceand eyelid signs (such as MGD), and recommended the key diag-nostic tests and techniques. While many tests have been suggestedto be diagnostic of DED, their sensitivity and specificity is highlydependent on the inclusion criteria and severity of the DED groupand the population examined. The Subcommittee made thefollowing recommendations to represent the best available evi-dence to diagnose and subtype DED in a clinical setting. The se-lection principles were: diagnostic ability; minimal-invasiveness;objectivity; and clinical applicability.

The recommended tests for the diagnosis of DED and assess-ment of its severity are presented in Fig. 5 Prior to diagnosis, it isimportant to exclude conditions that can mimic DED with a num-ber of triaging questions (Fig. 5). Such conditions and their differ-entiating features are outlined in the report. Following this, the DryEye Questionnaire-5 (DEQ-5) or Ocular Surface Disease Index(OSDI) should be completed to indicate whether a patient mighthave DED, and a positive symptom score on either of these ques-tionnaires should then trigger a more detailed examination forclinical signs of DED. The presence of any one of three specifiedsigns; reduced non-invasive break-up time; elevated or a largeinterocular disparity in osmolarity; or ocular surface staining (ofthe cornea, conjunctiva or lid margin) in either eye, is consideredrepresentative of disrupted homeostasis, confirming the diagnosisof DED. If a patient has DED symptoms and their practitioner doesnot have access to all these tests, a diagnosis is still possible, basedon a positive result for any one of the markers, but may requirereferral for confirmation if the available homeostasis markers arenegative. Guidance on how, and in which order, to conduct thesetests are provided within the report and videos are available on theTFOS website (www.tearfilm.org).

Having confirmed that the condition is DED on the basis of apositive symptom score and one or more positive homeostaticmarker results, further subtype classification tests such as mei-bography, lipid interferometry and tear volume measurementshould be conducted to determine: 1) where the DED falls on thespectrum between ADDE and EDE, and 2) the severity of DED, inorder to guide treatment.


http://www.tearfilm.org

Fig. 5. Recommended diagnostic approach for DED. Please see the original report for a complete description of this figure [11].


10. Management and therapy [12]

Themanagement of DED is complicated, due to its multifactorialetiology. Expanding upon the simple belief that “diagnosis pre-cedes therapy”means that cliniciansmustmake their best efforts toidentify the degree towhich EDE, ADDE and/or other ocular surfaceconditions are contributing to the patient's presentation. Thisaspect of determining themajor causative factors behind the DED iscritical to appropriate management.

The ultimate aim of DED management is to restore the ho-meostasis of the ocular surface and tear film, through breaking thevicious cycle of the disease. While certain treatments may be spe-cifically indicated for one particular aspect of an individual patient'scondition, a number of therapies might be appropriately recom-mended in order to treat the multiple aspects of a patient's pre-sentation with DED. While aiming to identify and treat the primarysource of the disease, the management of DED typically involvesongoing management to address chronic sequelae, rather thanshort-term treatment.

The presented management algorithm is not proposed as a rigid


sequential approach to be followed linearly. Instead, it should beviewed as an organizational tool to help guide initiation of treat-ment with those interventions most likely to benefit most patientswith DED, and progressing to more advanced and specific treat-ments aimed at particular aspects of the DED pathophysiology. On-going scientific evidence, as well as risk versus benefit and costconsiderations, will also contribute to decisions made in choosingbetween multiple treatment options.

Management algorithms are often constructed to recommend asequence of treatments according to the stage of disease, but thisconstruction is complicated in DED, as the disease often varies frompatient to patient, both in severity and in character. Table 4 lists aseries of management and treatment options that have all beenshown to result in alleviation of presenting DED [12]. Should pa-tients not respond to a given level of management, or should theypresent with more severe DED, the next level of management isrecommended and in some cases the previous therapy may becontinued in addition to any new therapies. In general, manage-ment approaches begin with conventional, low-risk and easilyaccessible patient-applied therapies such as over-the-counter


Table 4Recommendations for the staged management and treatment of DED.a,b,c

Step 1:� Education regarding the condition, its management, treatment and prognosis� Modification of local environment� Education regarding potential dietary modifications (including oral essential fatty acid supplementation)� Identification and potential modification/elimination of offending systemic and topical medications� Ocular lubricants of various types (if MGD is present, then consider lipid-containing supplements)� Lid hygiene and warm compresses of various typesStep 2:If above options are inadequate consider:� Non-preserved ocular lubricants to minimize preservative-induced toxicity� Tea tree oil treatment for Demodex (if present)� Tear conservation

� Punctal occlusion� Moisture chamber spectacles/goggles

� Overnight treatments (such as ointment or moisture chamber devices)� In-office, physical heating and expression of the meibomian glands (including device-assisted therapies, such as LipiFlow)� In-office intense pulsed light therapy for MGD� Prescription drugs to manage DEDd

� Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)� Topical corticosteroid (limited-duration)� Topical secretagogues� Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)� Topical LFA-1 antagonist drugs (such as lifitegrast)� Oral macrolide or tetracycline antibiotics

Step 3:If above options are inadequate consider:� Oral secretagogues� Autologous/allogeneic serum eye drops� Therapeutic contact lens options

� Soft bandage lenses� Rigid scleral lenses

Step 4:If above options are inadequate consider:� Topical corticosteroid for longer duration� Amniotic membrane grafts� Surgical punctal occlusion� Other surgical approaches (eg tarsorrhaphy, salivary gland transplantation)

MGD e meibomian gland dysfunction; DED e dry eye disease.a Potential variations within the disease spectrum are acknowledged to exist between patients and the management options listed above are not intended to be exclusive.

The severity and etiology of the DED state will dictate the range and number of management options selected from one or more steps.b One or more options concurrently within each category can be considered within that step of the dry eye disease state. Options within a category are not ranked according

to importance and may be equally valid.c It should be noted that the evidence available to support the various management options differs and will inevitably be lower for newer management options. Thus, each

treatment option should be considered in accordance with the level of evidence available at the time management is instigated.d The use of prescription drugs needs to be considered in the context of the individual patient presentation, and the relative level of evidence supporting their use for that

specific indication, as this group of agents differs widely in mechanism of action.


lubricants for early stage disease, and progress to more advancedtherapies for more severe forms of DED. However, it must be un-derstood that there is significant heterogeneity in the DED patientpopulation. The approach cannot be overly formulaic and theserecommendations may be modified and overlapped as required bypractitioners based on an individual patient profile.

The expected treatment trial duration before concluding failureto improve is related both to the individual's response and to thetherapy being considered. Most commonly, treatment effects areobservedwithin one to threemonths, although some therapies (e.g.cyclosporine A) may take longer.

Overall, the treatment of DED remains something of an art, noteasily lending itself to a rigid, evidence-based algorithm that ac-commodates all patients with DED symptoms or signs. All eye careproviders who treat patients with DED must exercise their clinicalskills to judge the significance of each of the varied pathogenicprocesses that may manifest similar subjective complaints andsimilar signs of ocular surface dysfunction.


11. Clinical trial design [13]

In order to improve the quality of clinical trials, to optimizeresources, and to increase the opportunity for novel therapeutics toreach patients with DED, the TFOS DEWS II Clinical Trials Sub-committee made the following recommendations.

First, that studies be conducted consistent with Good ClinicalPractice (GCP). While this may be a daunting task, clinical trialistsshould consult colleagues and drug development experts who arefamiliar with this system of controls. This includes appropriateprotections for the study subjects. GCP also requires compliancewith appropriate regulatory requirements in the jurisdiction ofstudy conduct, and may require additional regulatory filings if theinvestigational shipment is prepared and sent from another state orcountry.

The Consolidated Standards of Reporting Trials (ConSORT)statement is useful to review prior to planning and starting a study.Next, the Subcommittee recommended that the design, treatments,and sample size be consistent with the investigational treatment,


Fig. 6. TFOS DEWS II™ report.


the objectives of the study, and the phase of development. Forexample, a crossover or paired-comparison design may be appro-priate for a comfort study in normal volunteers, but not for a long-lasting treatment with potential for systemic or contralateral ef-fects. Also, the dose of a drug or biologic should not only be lessthan that whichwas toxic or not tolerated in nonclinical or previousclinical studies, but must be sufficient, in dose and frequency, todeliver therapeutic concentrations at the intended site of action.The duration of treatment, at least for a pivotal study, should also beconsistent with the mechanism of action and time course of effect.For pivotal studies, sample size is key to the potential validity of thestudy.

Outcome measures are critical to determine the efficacy of thetreatment and, if possible, should include minimally invasiveobjective metrics that align with the expected mechanism ofaction of the treatment. Exploration of new ways to evaluateDED, such as biomarkers, may lead to improvement in DEDclinical trial design and increased clarity on the efficacy of newtreatments.

Dedication

This TFOS DEWS II report is dedicated to the late Professor JuhaHolopainen (Helsinki Eye Lab and Department of Ophthalmology,University of Helsinki and Helsinki University Hospital, Helsinki,Finland), who served on the Steering Committee and Tear FilmSubcommittee, in recognition of his outstanding scientific contri-butions to the field of the ocular surface and tear film.

Acknowledgments

The authors thank Amy Gallant Sullivan (TFOS Executive Di-rector, USA) for raising the funds that made this TFOS DEWS IIpossible; Amy and Rose M. Sullivan (TFOS Operations Manager,USA) for their help in the organization of this Workshop; NinoLongo (Catania, Italy) and Sabrina Zappia (Rome, Italy) for theirillustrative expertise (e.g. Figs. 1, 5 and 6); Stephanie Wong(University of Waterloo, Canada) for her technical assistance; andall participants of TFOS DEWS II for their contributions to thisreport.

The TFOS DEWS II was supported by unrestricted donationsfrom Alcon, Novartis, Shire, Allergan, Bausch þ Lomb, Akorn,CooperVision, Domp�e, Horus Pharma, Lmbris Biopharma, Oculeve,TearLab, Laboratoires Th�ea, SIFI, Sun Pharma, Johnson & JohnsonVisionCare, Carl Zeiss Meditec, Quint Health, Scope Ophthalmicsand Senju.


References

[1] Nelson JD, Craig JP, Akpek E, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS IIintroduction. Ocul Surf 2017;15:269e75.

[2] Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS IIdefinition and classification report. Ocul Surf 2017;15:276e83.

[3] Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOSDEWS II epidemiology report. Ocul Surf 2017;15:334e65.

[4] 2007 TFOS report of the international dry eye workshop (DEWS). Ocul Surf2007:65e204.

[5] Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, et al.TFOS DEWS II sex, gender, and hormones report. Ocul Surf 2017;15:284e333.

[6] Institute of Medicine (US) Committee on Understanding the Biology of Sexand Gender Differences. Exploring the biological contributions to humanhealth: does sex matter?. Washington, DC: The National Academies Press;2001.

[7] Bron AJ, dePaiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWSII pathophysiology report. Ocul Surf 2017;15:438e510.

[8] Willcox MDP, Argüeso P, Georgiev G, Holopainen J, Laurie G, Millar T, et al.TFOS DEWS II tear film report. Ocul Surf 2017;15:366e403.

[9] Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOSDEWS II pain and sensation report. Ocul Surf 2017;15:404e37.

[10] Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J,et al. TFOS DEWS II iatrogenic dry eye report. Ocul Surf 2017;15:511e38.

[11] Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al.TFOS DEWS II diagnostic methodology report. Ocul Surf 2017;15:539e74.

[12] Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al.TFOS DEWS II management and therapy report. Ocul Surf 2017;15:575e628.

[13] Novack GD, Asbell P, Barabino B, Bergamini MVW, Ciolino JB, Foulks GN, et al.TFOS DEWS II clinical trial design report. Ocul Surf 2017;15:629e49.


http://refhub.elsevier.com/S1542-0124(17)30214-8/sref1http://refhub.elsevier.com/S1542-0124(17)30214-8/sref1http://refhub.elsevier.com/S1542-0124(17)30214-8/sref1http://refhub.elsevier.com/S1542-0124(17)30214-8/sref2http://refhub.elsevier.com/S1542-0124(17)30214-8/sref2http://refhub.elsevier.com/S1542-0124(17)30214-8/sref2http://refhub.elsevier.com/S1542-0124(17)30214-8/sref3http://refhub.elsevier.com/S1542-0124(17)30214-8/sref3http://refhub.elsevier.com/S1542-0124(17)30214-8/sref3http://refhub.elsevier.com/S1542-0124(17)30214-8/sref4http://refhub.elsevier.com/S1542-0124(17)30214-8/sref4http://refhub.elsevier.com/S1542-0124(17)30214-8/sref4http://refhub.elsevier.com/S1542-0124(17)30214-8/sref5http://refhub.elsevier.com/S1542-0124(17)30214-8/sref5http://refhub.elsevier.com/S1542-0124(17)30214-8/sref5http://refhub.elsevier.com/S1542-0124(17)30214-8/sref6http://refhub.elsevier.com/S1542-0124(17)30214-8/sref6http://refhub.elsevier.com/S1542-0124(17)30214-8/sref6http://refhub.elsevier.com/S1542-0124(17)30214-8/sref6http://refhub.elsevier.com/S1542-0124(17)30214-8/sref7http://refhub.elsevier.com/S1542-0124(17)30214-8/sref7http://refhub.elsevier.com/S1542-0124(17)30214-8/sref7http://refhub.elsevier.com/S1542-0124(17)30214-8/sref8http://refhub.elsevier.com/S1542-0124(17)30214-8/sref8http://refhub.elsevier.com/S1542-0124(17)30214-8/sref8http://refhub.elsevier.com/S1542-0124(17)30214-8/sref9http://refhub.elsevier.com/S1542-0124(17)30214-8/sref9http://refhub.elsevier.com/S1542-0124(17)30214-8/sref9http://refhub.elsevier.com/S1542-0124(17)30214-8/sref10http://refhub.elsevier.com/S1542-0124(17)30214-8/sref10http://refhub.elsevier.com/S1542-0124(17)30214-8/sref10http://refhub.elsevier.com/S1542-0124(17)30214-8/sref11http://refhub.elsevier.com/S1542-0124(17)30214-8/sref11http://refhub.elsevier.com/S1542-0124(17)30214-8/sref11http://refhub.elsevier.com/S1542-0124(17)30214-8/sref12http://refhub.elsevier.com/S1542-0124(17)30214-8/sref12http://refhub.elsevier.com/S1542-0124(17)30214-8/sref12http://refhub.elsevier.com/S1542-0124(17)30214-8/sref13http://refhub.elsevier.com/S1542-0124(17)30214-8/sref13http://refhub.elsevier.com/S1542-0124(17)30214-8/sref13

12 ADVANCED OCULAR CARE | SEPTEMBER 2016

BEA

UTY

AN

D A

ESTH

ETIC

S

Dirty secrets inside the beauty bag.

BY LESLIE E. O’DELL, OD; AMY GALLANT SULLIVAN, BS; AND LAURA M. PERIMAN, MD

SUFFERING FOR BEAUTY: HARMFUL INGREDIENTS AND TRENDS IN COSMETICS

The United States has the largest cosmetics market in the world, and its revenue is expected to

exceed $62 billion in 2016.1 According to the consulting com-pany Kline, natural cosmetics and skincare is estimated to be worth $33 billion, accounting for 13% of the overall global beau-ty market.2 There is also a growing demand for safe cosmetics.

Part one of this four-part series (“Beauty Does Not Have to Hurt,” page 42, AOC’s July/August 2016 issue) discussed the lack of regulatory oversight by the US Food and Drug Administration over the use of terms such as safe in the labeling of cosmetics. With cosmetics being a large and growing market, it is necessary for eye care providers to know the habits of our patients, both men and women, and to educate them about proper ocular health and cos-metic use. In part two of the series, we explore potential harms from ingredients in commonly used cosmetics, and we uncover some potentially harmful beauty trends.

NATURALLY ORGANIC OCULAR SURFACE OFFENDERS

“Nature” is all the rage in beauty and wellness products. Particularly trendy at the moment are earthy ingredients—like rocks. And the rocks that are very popular are diamonds, and not just those for sparkling adornment.

Actress Elizabeth Taylor once professed “Big girls need big diamonds.” However, Ms. Taylor was referring to diamonds as jewels, not the crushed rocks we now find in luxury beau-ty products. Diamonds are a form of carbon, a very hard

mineral. They are used not only as gemstones, but also as industrial abrasives for cutting hard materials. On your face, it is claimed that diamond dust acts like a magic wand, eras-ing sun damage, scars, blotchiness, and lines.

Diamond dust is most often found in luxury eye cosmet-ics, making their prices out of reach for younger consumers. Therefore, the demographic most attracted to diamond-infused products is women in middle-age; this happens to coincide with the time many women begin to develop ocu-lar surface disease (OSD).3

Can diamond dust exacerbate dry eye symptoms? Crushed rocks in the tear film? Yes, perhaps that might cause some instability. On slit-lamp examination, these crushed rocks look like shards of glass piercing the conjunctival tissue.

Adding flame to this inflammatory fire, many luxury cosmetic brands have now expanded their natural mineral ingredients to include not only diamond dust, but also hematite and tourmaline in their products.

Figure 1. Eyelash length should be one-third of eye width.

Eyelashes help limit tear evaporation from the surface of

the eye.

SEPTEMBER 2016 | ADVANCED OCULAR CARE 13

BEA

UTY

AN

D A

ESTHETIC

S

Ms. Taylor might opine that these precious stones should be adorning fingers, ears, and throats, not the eyelids or eye contours.

Another natural mineral ingredient that should raise an eyebrow is kohl. Kohl has been popular since ancient times, used by the queens and nobles of Egypt as early as 3100 BCE.4 Historically, people used kohl to protect their eyes from the harsh rays of the sun, as well as for treatment of eye ailments. In India, mothers applied kohl to their infants’ eyes soon after birth, purportedly to strengthen the chil-dren’s eyes, and others believed it could prevent children from being cursed by the evil eye.5-10

The Food and Drug Administration points out, however, that many people may be unaware of the lead-poisoning risk, for both adults and children, from this traditional eye cosmetic, known variously as kohl, kajal, al-kahl, and surma. Kohl is predominantly used as an eyeliner or mascara, both for beautification and as part of cultural tradition. Concerns about kohl’s safety should be addressed with patients.

EYELASHES: BALANCING BEAUTY AND FUNCTION

In most Western cultures, long eyelashes are deemed aesthetically pleasing. However, when we alter the ratio that Mother Nature intended, we create unwanted con-sequences. The long eyelashes of babies have an adorable appeal, but babies do not experience the same effects of altered lash/lid ratio as adults. Perhaps the incredible tear stability of the young and the long lashes of infancy are designed to maximally deflect debris, an advantage given the relative lack of neurologic coordination and mobility of infancy. Or perhaps it is an illusion that the lashes are longer in the young and that the ideal protective lash/lid length ratio is preserved in infancy.

Alterations of length have been found to limit the eyelashes’ unique protective features against turbulent air and debris.11 When individuals artificially lengthen their eyelashes with cosmetics, stiff methacrylate eyelash extension glues, and syn-thetic lash extension fibers, the natural lash cilia flexion and resultant tear evaporation and debris-deflecting attribute may also be detrimentally altered (Figure 1).

Amador et al found that, among 22 mammalian spe-cies studied in wind tunnel experiments, the optimal lash/lid ratio of 0.34 cuts the tear evaporation rate and particle deposition rate by half.11 Eyelashes become thinner, shorter, and lighter as women age,12 and this may contribute to the evaporative load in older patients with OSD.

Alterations in the ideal lash/lid ratio are also seen in children with significant ocular allergies such as vernal keratoconjunctivitis (VKC). In a series of 93 children with VKC, Pucci et al found the eyelash length to be significantly longer than in normal age- and gender-matched controls.13

Additionally, the degree of VKC severity was positively cor-related with longer lash length.13

Eyelash extensions are popular, but for OSD specialists there are concerns about the consequences. As noted, altering the ideal lash/lid ratio results in altered evapora-tive and debris protective abilities, but in addition the adhesives used for these extensions also create havoc for the ocular surface. These adhesives are cyanoacrylate- like adhesives, with mixtures of methacrylates, volatile organic compounds, and formaldehyde (a preservative and known ocular irritant). Methacrylates are considered inert once they polymerize, but the accompanying chemicals needed to keep the acrylates in liquid form during application contribute to evaporative stress, irritation, and allergenic-ity. Additionally, these chemicals can leech onto the ocu-lar surface during application of the adhesive, creating a chemical conjunctivitis (Figure 2).

Figure 2. This young patient had false lashes applied (A).

She developed a severe chemical conjunctivitis from the

glue used during the application process (B).

A

B

14 ADVANCED OCULAR CARE | SEPTEMBER 2016

BEA

UTY

AN

D A

ESTH

ETIC

S

Based on the available literature and clinical observations, eye care providers should advise OSD patients to avoid eyelash extensions and growth serums. Many patients with severe OSD stop using eyelid and eyelash cosmetics due to irritation. Eyelash growth products such as Latisse (bimatoprost ophthal-mic solution 0.03%, Allergan), although shown to be “safe and effective”,14 the incidence of conjunctival and eyelid hyperemia was significantly greater in subjects using 0.03% bimatoprost than subjects randomized to a vehicle control.15 Also, accord-ing to a very recent study, prostaglandin analogues (eg, bima-toprost) may induce meibomian gland dysfunction.16

EYELIDS: NO SILVER LININGLining the eyelid is another common way to enhance the

eyes. Eyeliners can be found in the form of pencils, cakes, liquids, and even permanent options. The location of

eyeliner application is influenced by fashion trends, which have included application close to the lash line, posterior to the lash line, and on the inner lid margin or waterline. Trends have also included the addition of bright pigments, glitter, and even gems.

It is important to make your make-up wearing patients aware of their eyelid anatomy, particularly the meibomian glands and their orifices. To the eye care practitioner, the lid is an area of great concern for overall tear film stability, but to patients this is the perfect place to apply eyeliner. Pencil eyeliner, when applied on the inner portion of the lash line, has been shown to migrate into the eye 15% to 30% of the time.17 Although eyeliner entering the ocular surface has not been shown to induce ocular inflammation, use on consecutive days has been shown to increase lipid layer thickness and the incidence of dry eye symptoms.17

Conjunctival pigmentation has also been noted in patients using eyelash cosmetics, including both mascara and eyeliner.18 This can be seen on slit-lamp examination as small brown or black flecks within the inferior palpebral conjunctival tissue.

Some women who want the luxury of waking up with makeup may elect to obtain permanent eyeliner in the form of tattoos (Figure 3). A recent study found that per-manent eyeliner tattooing shortened tear film breakup time, increased corneal staining, and induced meibomian gland loss significantly in comparison with a control group with no eyeliner tattoos.19

Eyelash dying or tinting is another beauty trend that can cause severe allergic reactions, as many hair dyes contain para-phenylenediamine, or PPD.20 This is a chemical found in plastics such as Kevlar (Dupont) and also used in the recent trend in henna temporary tattoos. Many individu-als have reported severe conjunctival reactions, swelling, watering, and acute inflammation due to allergy to PPD in dyes used around the eyes for eyelash tinting.21-22

DIRTY SECRETS: INSIDE THE BEAUTY BAG You can recommend that your patients use cosmetics

containing safer ingredients, and you can educate them about the proper application of cosmetics. The next prob-lem is assuring their compliance. One common way in which patients may fall short of our expectations is in the timely replacement of cosmetics.

Quarterly replacement of eyelash (mascara and eyeliner) and eyelid (primers and eye shadow) cosmetics is a common recommendation. How many of your patients do this? Have you discussed their cosmetic hygiene routines with them? Cosmetics are not like the bottle of milk in your refrigera-tor: They do not have a “use by” date stamped on them. Nonetheless, these makeup products do have built-in expira-tion dates. Tell your patients to treat products such as mascara and liquid eyeliner like eggs, as they have the shortest shelf lives.

Figure 3. Permanent eyeliner in the form of a tattoo is com-

mon in the United States (A). This practice can affect tear

film quality and meibomian gland function (B). Education

about the risks of these permanent procedures is key for

patients with dry eye disease.

A

B

SEPTEMBER 2016 | ADVANCED OCULAR CARE 15

BEA

UTY

AN

D A

ESTHETIC

S

Mascaras and eyeliners are made up of oil, waxes, preser-vatives, and pigments. Most of our female patients use eye makeup; it has been estimated that 87% of women younger than 55 years use eye cosmetics.23 It has been estimated that 9 out of 10 women 18 to 54 years of age use mascara.24

These oils and waxes can not only clog the meibomian glands, they can also supplement the diet of Demodex. Optometrists should make patients aware of Demodex before an infestation can occur. Not only should you discuss Demodex and the need for lid hygiene with your patients, but you should address bacterial growth and contamination of makeup tubes and containers and how this can affect vision. You might point out that, every time they put the wand back into the tube, bacteria enter and contaminate the makeup.

Microbial organisms are normally present on human eye-lashes. Application of eye makeup to lashes has the poten-tial to inoculate the mascara tube or eyeliner with these microbes.25 Mascaras are generally contaminated more than eye shadows. In a study of 150 samples, 15% of mascaras were rated as heavily contaminated (more than 104 cfu/mL of bacteria).26

Pack et al, upon finding microbial presence in 36.4% of mascara tubes cultured after 3 months of use, recommend-ed keeping a mascara tube, used on a daily basis, for no more than 3 months.25

Pseudomonas corneal ulcers have also been associated with mascara contaminated with P aeruginosa.27 If the cor-neal epithelium is scratched during the application of mas-

cara, particularly with an old applicator, the cornea should be treated immediately and the mascara cultured to detect Pseudomonas. This is important to remember, as mascara wand injuries are common with makeup application in moving vehicles, another dirty secret of our cosmetic-loving patients. Aged mascara wands, tubes, and eyeliners can easi-ly become contaminated with one or more species of micro-organisms including the genera Bacillus spp., Staphylococcus spp., Pseudomonas spp., Proteus vulgaris, and Serratia marc-escens.27 Patients should also be made aware that they must wash their hands before makeup application. Contaminants can appear from multiple sources.

Traditionally, the contents in your patient’s purse should not be public knowledge, however, what’s in their beauty bag can be detrimental to their eye health. Please discuss your patients’ cosmetic routine and OSD implications. Stay vigilante to new beauty trends and start the conversation early about cosmetic use with your patients, what’s hiding in their beauty bag can hurt the ocular surface. n

1. MarketResearch.com http://www.prnewswire.com/news-releases/marketresearchcom-the-us-beauty-and-cosmetics-market-expected-to-exceed-62-billion-in-2016-300209081.html2. http://www.cosmeticsdesign-europe.com/Market-Trends/The-lowdown-on-all-that-s-new-in-the-natural-and-organic-market.3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003:136;318-326.4. Lucas A. Cosmetics, perfumes and incense in ancient Egypt. J Egypt Archaeol. 1930;16(1/2):41-53. 5. Al-Hazzaa SA, Krahn PM. Kohl: a hazardous eyeliner. Int Ophthalmol. 1995;19(2):83-88.6. Alkhawajah AM. Alkohl use in Saudi Arabia: extent of use and possible lead toxicity. Trop Geogr Med. 1992;44(4):373-377.7. Hardy AD, Walton RI, Myers KA, Vaishnav R. Availability and chemical composition of traditional eye cosmetics (“kohls”) used in the United Arab Emirates of Dubai, Sharjah, Ajman, Umm Al-Quwain, Ras Al-Khaimah, and Fujairah. J Cosmet Sci. 2006;57(2):107-125.8. Jallad KN, Hedderich HG. Characterization of a hazardous eyeliner (kohl) by confocal Raman microscopy. J Hazard Mater.

Young women and men often turn to YouTube to learn the latest trends in beauty and to find how-to guides for makeup application. In the past 10 years, more than 5 billion hours of beauty tutorials and explainers have been uploaded to YouTube.

Some of the videos offering tips on makeup application may be quite alarming to eye care providers. There are makeup challenges, such as applying 100 layers of mascara or founda-tion. There are do-it-yourself guides for making cosmetics—using anything from blueberries to crushed Oreo cookies.

Thanks to tips from celebrities like Taylor Swift, we have to be concerned about young women using Sharpie markers as liquid eyeliner. The Kardashian family is not much help either, having made false eyelashes and heavy use of eyeliner mainstream.

Stay vigilant to new beauty trends, and start conversations about proper cosmetic use early with your young patients.

MAKEUP TIPS IN THE YOUTUBE ERA

BEA

UTY

AN

D A

ESTH

ETIC

S

2005;124(1-3):236-240.9. Nir A, Tamir A, Zelnik N, Iancu TC. Is eye cosmetic a source of lead poisoning? Isr J Med Sci. 1992;28(7):417-421.10. Parry C, Eaton J. Kohl: a lead-hazardous eye makeup from the third world to the first world. Environ Health Perspect. 1991;94:121-123.11. Amador GJ, Mao W, DeMercurio P, et al. Eyelashes divert airflow to protect the eye. J R Soc Interface. 2015;12(105). pii: 20141294. 12. Glaser DA, Jones D, Carruthers J, et al. Epidemiologic analysis of change in eyelash characteristics with increasing age in a population of healthy women. Dermatol Surg. 2014;40(11):1208-1213.13. Pucci, N, Novembre E, Lombardi E, et al. Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics. 2005;115(1):e86-e91.14. Woodward JA, Haggerty CJ, Stinnett SS, et al. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 2010;9(2): 96-102.15. Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter,randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66(5):801-6.16. Kam WR, Liu Y, Ding J, Sullivan DA. Do cyclosporine A, an IL-1 receptor antagonist, uridine triphosphate, rebamipide, and/or bimatoprost regulate human meibomian gland epithelial cells? Invest Ophthalmol Vis Sci. 2016;57(10):4287-4294.17. Ng A, Evans K, North RV, Purslow C. Migration of cosmetic products into the tear film. Eye Contact Lens. 2015;41(5):304-309.18. Sugar HS, Kobernick S. Subconjunctival pigmentation; associated with the use of eye cosmetics containing carbon-black. Am J Ophthalmol. 1966;62(1):146-149.19. Lee YB, Kim JJ, Hyon JY, et al. Eyelid tattooing induces meibomian gland loss and tear film instability. Cornea. 2015;34(7):750-755.20. Teixeira M, de Wachter L, Ronsyn E, Goossens A. Contact allergy to para-phenylenediamine in a permanent eyelash dye. Contact Dermatitis. 2006;55(2):92-94.21. Hansson C, Thorneby-Andersson K. Allergic contact dermatitis from 2-chloro-p phenylenediamine in a cream dye for eyelashes and eyebrows. Contact Dermatitis. 2001;45:235-236.22. Kaiserman I. Severe allergic blepharoconjunctivitis induced by a dye for eyelashes and eyebrows. Ocul Immunol Inflamm. 2003;11:149-151. 23. Ng A, Evans K, North RV, et al. Impact of eye cosmetics on the eye, adnexa, and ocular surface. Contact Lens. 2016 Jul;42(4):211-20. doi: 10.1097/ICL.0000000000000181.24. https://www.npd.com/wps/portal/npd/us/news/press-releases/pr_081125/25. Pack LD, Wickham MG, Enloe RA, Hill DN. Microbial contamination associated with mascara use. Optometry.

2008;79(10):587-593.26. Wilson LA, Julian AJ, Ahearn DG. The survival and growth of microorganisms in mascara during use. Am J Ophthalmol. 1975;79(4):596-601.27. Wilson LA, Ahearn DG. Pseudomonas-induced corneal ulcers associated with contaminated eye mascaras. Am J Ophthalmol. 1977;84:112-119.

Leslie E. O’Dell, ODn Director of Dry Eye Center of PA, Wheatlyn Eye Care,

Manchester, Pennsylvanian 717) 266-5661; (717) 521-7161; [email protected] [email protected]; Twitter @helpmydryeyesn Financial disclosure: speaker for Allergan, RPS, and Shire; con-

sultant to Bruder and Paragon BioTeck

Laura M. Periman, MDn Specialist in cornea and external disease, Seattlen [email protected]; (206) 234 9846n Financial disclosure: speaker for Allergan, BioTissue, and

TearScience; consultant to Allergan

Amy Gallant Sullivan, BSn Executive Director and Board member, Tear Film & Ocular

Surface Society (TFOS), Bostonn [email protected]; Twitter @Eyeppl @DryEyeMakeup

42 ADVANCED OCULAR CARE | JULY/AUGUST 2016

COV

ER F

OCU

S

The US Food and Drug Administration (FDA) requires that ocular prescription medications scientifi-cally demonstrate a statistically significant improvement in the

signs and symptoms of disease. Without demonstrating efficacy and safety, new pharmaceuticals do not receive FDA approval. Prescription medications that we recom-mend for our patients with dry eye disease (DED) have proven safety and efficacy documented through rigorous clinical trial studies. Unfortunately, the cosmetics that our patients use in and around their eyes daily are not required to meet such high standards.

The Breast Cancer Fund reported that the average woman in the United States uses 12 cosmetic products daily, and the average man uses six.1 More than 10,000 chemicals are used to create these products, and less than 20% of these ingredients have been proven to be safe. These chemicals, many of them synthetic and industrial chemicals, when absorbed into the body, can act as car-cinogens, endocrine disruptors, neurotoxins, and repro-ductive toxins.

The FDA regulates makeup, products such as lipstick, blush, foundation, eyeliner, eye shadow, and mascara, as cosmetics under the Federal Food, Drug, and Cosmetic Act. In 1938, this statute was enacted after 100 patients died from using a sulfanilamide medication. In the manu-facture of this medication, diethylene glycol, a cousin of poisonous antifreeze, had been used to dissolve it into liquid form.2 The FDA defines cosmetics by their intended use: that is, “articles intended to be rubbed, poured, sprin-kled, or sprayed on, introduced into, or otherwise applied to the human body ... for cleansing, beautifying, promot-ing attractiveness, or altering the appearance.”3

Cosmetics labeling laws available on the FDA’s website note that “ingredients must be declared in descend-ing order of predominance” and “ingredients present

at a concentration not exceeding 1% may be listed in any order after the listing of the ingredients present at more than 1% in descending order of predominance.” “The Federal Food, Drug and Cosmetics Act (FFDCA) includes 112 pages of standards for food and drugs, but just a single page for cosmetics. The cosmetics title of the

BEAUTY DOES NOT HAVE TO HURT

Ocular surface disease can be exacerbated by chemicals hiding in plain sight in everyday products. This is the first of a three part series.

BY LESLIE E. O’DELL, OD; AMY GALLANT SULLIVAN, AND LAURA M. PERIMAN, MD

Figure 1. Diagram adapted from the TFOS Dry Eye

WorkShop 2007 report illustrates the problem of cosmetics

ingredients and detergent loads for the DED patient. The

stars have been added to highlight the multiple mechanisms

by which cosmetics and detergents have the potential to

contribute to the mechanisms of DED.

The Breast Cancer Fund reported that the average woman in the United States uses 12 cosmetic products daily, and the average man uses six.

“

JULY/AUGUST 2016 | ADVANCED OCULAR CARE 43

COV

ER FOCU

S

FFDCA ... provides virtually no power to perform even the most rudimentary functions to ensure the safety of an estimated $71 billion cosmetic industry.” This according to the Campaign for Safe Cosmetics, a Project of Breast Cancer Fund. In 2015, Senators Dianne Feinstein (D-CA) and Susan Collins (R-ME) introduced legislation to update the regulations covering cosmetics and personal care products for the first time in 75 years.

In the United States, 11 chemicals are banned from use in cosmetics (see Chemicals Banned from Use in Cosmetics in the United States). This is a remarkably low number in comparison with the situations in the European Union (EU), Canada, and Japan. The EU Cosmetic Directive, enacted in 2003 and updated in 2013, bans 1,328 chemi-cals from cosmetics due to risks of cancer, genetic muta-tion, reproductive harm, or birth defects. The EU also requires premarket safety assessment and mandatory registration of cosmetics, neither of which are required in the United States.

Figure 1 illustrates the problem of cosmetics ingredients and detergent loads for the DED patient.

HIDING IN PLAIN SIGHTRemember when you started reading food labels?

Your eyes were opened to all of the additives present in processed foods. Similarly, reading cosmetics labels can be overwhelming at first. Once you learn the chemical vocabulary, however, you begin to understand the scope and extent of the problem.

Sodium Laureth SulfatesA top selling, “dermatologist recommended” facial wash

may not be ideal for use around the delicate and specialized skin of eyelids. Many facial washes and cleansers contain

sodium laureth sulfates that over-strip the delicate oils of the eyelids, contributing to the evaporative burden of the ocular surface. Mouse models of desiccating stress showed that the protein-to-lipid ratio of mature meibum suffered under the increased demands of desiccating stress in a controlled adverse environment.5 Imagine the desiccating stress of iatrogenically stripping your oil reservoir every day, sometimes tw

dry eye disease...introduction dry eye disease (ded) afflicts hundreds of millions of people...

Documents